Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
cAd3-EBO Z and MVA-BN Filo in Healthy Adults
NCT02240875Phase 1Completed
- Sponsor
- University of Oxford
- Start
- Sep 2014
- Primary completion
- Aug 2017
- Modality
- Viral Vector Vaccines, Viral Vectors
- Countries
- 1
01
Overview
Phase 1, open-label trial of cAd3-EBOV and Mvabea in Ebola virus disease (EVD) (13 arms), sponsored by University of Oxford. Primary endpoint: Safety and tolerability of the Ebola Zaire vaccine cAd3-EBO Z at 6 months. Started Sep 2014; status: completed.
02
Drugs
cAd3-EBOVMvabea
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT02240875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02240875.